|
Adenocarcinoma
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Similarly, TAZ mRNA level was higher in SRCC than in adenocarcinoma (P = 0.003).
|
24707483 |
2014 |
|
Adenocarcinoma of colon
|
0.010 |
Biomarker
|
disease |
BEFREE |
The present study aimed to investigate the role of Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ) in the LOVO human colon adenocarcinoma cell line and explore the underlying mechanisms.
|
29042987 |
2017 |
|
Adenocarcinoma of lung (disorder)
|
0.020 |
Biomarker
|
disease |
BEFREE |
Mining available gene expression data sets allowed to observe that high co-expression levels of SCD1, β-catenin, YAP/TAZ and downstream targets have a strong negative prognostic value in lung adenocarcinoma.
|
28368399 |
2017 |
|
Adenocarcinoma of lung (disorder)
|
0.020 |
Biomarker
|
disease |
BEFREE |
The present study aimed to investigate whether TAZ is involved in cisplatin sensitivity in lung adenocarcinoma.
|
28737828 |
2017 |
|
Adult Angiosarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Genetic characterization of several soft tissue tumour types that occur in the skin has resulted in the identification of diagnostically useful markers: ALK gene rearrangement with corresponding ALK protein expression by immunohistochemistry in epithelioid fibrous histiocytoma; the WWTR1-CAMTA1 fusion gene with CAMTA1 protein expression in epithelioid haemangioendothelioma; MYC amplification and overexpression in radiation-associated angiosarcoma; and EWSR1 gene rearrangement in cutaneous myoepithelial tumours.
|
26763770 |
2016 |
|
Adult Epithelioid Hemangioendothelioma
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
The chimeric WWTR1/CAMTA1 transcription factor may represent a therapeutic target for EHE and offers the opportunity to shed light on the functions of two poorly characterized proteins.
|
21885404 |
2011 |
|
Adult Epithelioid Hemangioendothelioma
|
0.090 |
Biomarker
|
disease |
BEFREE |
The WWTR1 (protein is known as TAZ)-CAMTA1 (WC) fusion gene defines epithelioid hemangioendothelioma, a malignant vascular cancer.
|
25961935 |
2016 |
|
Adult Epithelioid Hemangioendothelioma
|
0.090 |
Biomarker
|
disease |
BEFREE |
Fluorescence in situ hybridization analysis showed CAMTA1-WWTR1 fusions in 4/7 low-grade and 23/23 intermediate-grade EHE (P<0.001).
|
25353289 |
2015 |
|
Adult Epithelioid Hemangioendothelioma
|
0.090 |
Biomarker
|
disease |
BEFREE |
Thus, we undertook a molecular analysis of six samples from two patients with multicentric hepatic EHE to test our hypothesis that the presence of identical breakpoints in WWTR1 and CAMTA1 support the monoclonal nature of multifocal EHE.
|
22429593 |
2012 |
|
Adult Epithelioid Hemangioendothelioma
|
0.090 |
Biomarker
|
disease |
BEFREE |
A WWTR1-CAMTA1 fusion is present in most classic epithelioid hemangioendothelioma, regardless of their clinical behavior, suggesting that additional genetic abnormalities might be responsible in driving a more aggressive biology.
|
31537895 |
2019 |
|
Adult Epithelioid Hemangioendothelioma
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
Subsequent reverse transcription-polymerase chain reaction (RT-PCR) confirmed in three EHE the WWTR1-CAMTA1 fusion product.
|
21584898 |
2011 |
|
Adult Epithelioid Hemangioendothelioma
|
0.090 |
GeneticVariation
|
disease |
BEFREE |
Our report provides the first case of intracranial EHE with molecular proof of WWTR1-CAMTA1 gene fusion.
|
30085199 |
2018 |
|
Adult Epithelioid Hemangioendothelioma
|
0.090 |
Biomarker
|
disease |
BEFREE |
Characterization of the genetics of EHE is important because targeted therapies toward products of the specific WWTR1-CAMTA1 gene fusion may have an impact in the near future.
|
28855107 |
2018 |
|
Adult Epithelioid Hemangioendothelioma
|
0.090 |
AlteredExpression
|
disease |
BEFREE |
His tumor expressed the EHE-specific fusion oncogene WWTR1-CAMTA1.
|
28598585 |
2017 |
|
Adult Glioblastoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
We reported that WIP knockdown in mtp53-expressing glioblastoma greatly reduced proliferation and growth capacity of cancer stem cell (CSC)-like cells and decreased CSC-like markers, such as hyaluronic acid receptor (CD44), prominin-1 (CD133), yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ).
|
29890731 |
2018 |
|
Adult Glioblastoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
When orthotopic glioblastoma mouse model implanted with TAZ knocked down cells, glioma growth was inhibited and survival period was prolonged.
|
27764783 |
2016 |
|
Adult Glioblastoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of miR-130b induced hyperactivation of the YAP/TAZ and enhanced expression of the Hippo signaling downstream genes CTGF and the pluripotency associated markers, including CD133, SOX2, Nanog, MYC and BMI1, leading to promotion of glioblastoma stem cell phenotype.
|
26241672 |
2015 |
|
Adult Liposarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
These results indicate that dedifferentiation in LS shifts the expression of TIMPs from type 4 to type 1, inducing more aggressive behavior and poor prognosis through YAP/TAZ activation, which can be prognostic markers and therapeutic targets for LS patients.
|
31074490 |
2019 |
|
Adult Liver Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
HepG2 liver cancer cell was used in the present study, and shRNA against TAZ was transfected into HepG2 cell to knockdown TAZ expression.
|
30881030 |
2019 |
|
Adult Undifferentiated Pleomorphic Sarcoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
At an RNA level, expression of WWTR1 or YAP1 predicts overall survival in undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.
|
27129148 |
2016 |
|
Alveolar rhabdomyosarcoma
|
0.310 |
Biomarker
|
disease |
CTD_human |
On the other hand, the YAP paralog transcriptional co-activator with PDZ-binding motif (TAZ) is overexpressed in alveolar rhabdomyosarcoma (aRMS) patients with poor survival.
|
31494105 |
2019 |
|
Alveolar rhabdomyosarcoma
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
On the other hand, the YAP paralog transcriptional co-activator with PDZ-binding motif (TAZ) is overexpressed in alveolar rhabdomyosarcoma (aRMS) patients with poor survival.
|
31494105 |
2019 |
|
Anaplasia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
These results indicate that dedifferentiation in LS shifts the expression of TIMPs from type 4 to type 1, inducing more aggressive behavior and poor prognosis through YAP/TAZ activation, which can be prognostic markers and therapeutic targets for LS patients.
|
31074490 |
2019 |
|
ANOPHTHALMIA AND PULMONARY HYPOPLASIA
|
0.010 |
Biomarker
|
disease |
BEFREE |
Recent exciting studies from different laboratories indicate that the activity of the transcriptional co-activators Yes-associated protein (YAP) and WW-domain-containing transcriptional co-activator with PDZ-binding motif (TAZ) play a critical role in the promotion and maintenance of PDAC operating as key downstream target of KRAS signaling.
|
31057295 |
2019 |
|
Arteriosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, our findings revealed a mechanism by which YAP/TAZ activation contributes to the pathogenesis of atherosclerosis.
|
30466081 |
2018 |